middle.news
Mayne Pharma Rebuts Cosette’s Material Adverse Change Claim Amid Acquisition Talks
2:00am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Mayne Pharma Rebuts Cosette’s Material Adverse Change Claim Amid Acquisition Talks
2:00am on Monday 2nd of June, 2025 AEST
Key Points
Cosette alleges a Material Adverse Change triggering consultation rights under the scheme deed
Mayne Pharma disputes the claim, citing full disclosure of financial and regulatory matters
No formal termination notice issued yet by Cosette despite consultation intentions
Mayne Pharma commits to progressing the acquisition scheme timetable
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE